Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast versus methotrexate for chronic plaque psoriasis
ACTRN12625001007426Phase 4Not yet recruiting
- Sponsor
- Khyber Teaching Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apremilast and methotrexate in psoriasis (2 arms), sponsored by Khyber Teaching Hospital. Primary endpoint: Efficacy comparison of apremilast versus methotrexate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
apremilastmethotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on ACTRN12625001007426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001007426.